In a significant move just three years post its highly successful IPO, Sana Biotechnology has announced a strategic restructuring that will likely reshape the company's future and impact. This overhaul will include layoffs and a refocused research directive, marking a notable shift in priorities
The pharmaceutical industry has long been a battleground for innovation, with companies around the globe constantly striving to outpace each other in developing cutting-edge therapies. Oncology, the branch of medicine that deals with cancer, has emerged as a focal point of this dynamic competition.
The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of
Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step
GC Biopharma and Novelty Nobility have announced a promising partnership aimed at developing a novel treatment for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). This condition leads to retinal damage and eventual blindness, making it a significant health
Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors,
